|
Segment Reporting of the Merck Group – Corporate and Other/Merck Group |
||||||||||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
Corporate and Other | |||||
|
€ million |
|
|
|
|
Q3 |
Q3 |
Jan.–Sep. |
Jan.–Sep. | ||
| ||||||||||
|
Sales |
|
|
|
|
– |
– |
– |
– | ||
|
Royalty, license and commission income |
|
|
|
|
– |
– |
– |
– | ||
|
Total revenues |
|
|
|
|
– |
– |
– |
– | ||
|
Gross margin |
|
|
|
|
– |
– |
– |
– | ||
|
Marketing and selling expenses |
|
|
|
|
–1.5 |
–1.0 |
–2.4 |
–2.4 | ||
|
Royalty, license and commission expenses |
|
|
|
|
– |
– |
– |
– | ||
|
Administration expenses |
|
|
|
|
–17.9 |
–17.4 |
–58.0 |
–51.6 | ||
|
Other operating expenses and income |
|
|
|
|
–4.3 |
–5.7 |
–14.6 |
–21.3 | ||
|
Research and development |
– |
– |
– |
– | ||||||
|
Operating result |
|
|
|
|
–23.8 |
–24.1 |
–73.8 |
–73.6 | ||
|
Exceptional items |
|
|
|
|
–0.2 |
– |
–17.5 |
–1.2 | ||
|
Earnings before interest and tax (EBIT) |
|
|
|
|
–23.9 |
–24.1 |
–91.3 |
–74.8 | ||
|
Net operating assets* |
|
|
|
|
– |
– |
17.8 |
74.7 | ||
|
Segment liabilities* |
|
|
|
|
– |
– |
–18.9 |
–14.9 | ||
|
Capital spending on property, plant and equipment |
|
|
|
–0.3 |
0.3 |
0.2 |
0.6 | |||
|
Investments in intangible assets |
|
|
|
|
–0.3 |
1.6 |
3.3 |
4.9 | ||
|
Depreciation and amortization |
|
|
|
|
–1.2 |
–1.2 |
–3.8 |
–2.3 | ||
|
Impairment losses |
|
|
|
|
- |
– |
-0.4 |
– | ||
|
Net cash flows from operating activities |
|
|
|
|
–84.6 |
–136.2 |
–446.3 |
–318.1 | ||
|
Net cash flows from investing activities |
|
|
|
|
–650.1 |
48.8 |
–917.6 |
1,384.8 | ||
|
Free cash flow |
|
|
|
|
–84.3 |
–127.9 |
–451.9 |
–324.6 | ||
|
Underlying free cash flow |
|
|
|
|
–125.1 |
–124.6 |
–492.7 |
–305.9 | ||
|
FCR in % |
|
|
|
|
– |
– |
– |
– | ||
|
ROS in % |
|
|
|
|
– |
– |
– |
– | ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
Merck Group | |||||
|
€ million |
|
|
|
|
Q3 |
Q3 |
Jan.–Sep. |
Jan.–Sep. | ||
|
Sales |
|
|
|
|
2,434.3 |
2,347.0 |
7,381.4 |
6,472.6 | ||
|
Royalty, license and commission income |
|
|
|
|
97.3 |
90.8 |
269.3 |
272.1 | ||
|
Total revenues |
|
|
|
|
2,531.6 |
2,437.8 |
7,650.7 |
6,744.7 | ||
|
Gross margin |
|
|
|
|
1,851.8 |
1,818.2 |
5,570.9 |
5,121.2 | ||
|
Marketing and selling expenses |
|
|
|
|
–586.3 |
–573.3 |
–1,782.9 |
–1,581.7 | ||
|
Royalty, license and commission expenses |
|
|
|
|
–133.9 |
–115.8 |
–363.7 |
–355.3 | ||
|
Administration expenses |
|
|
|
|
–124.5 |
–128.0 |
–375.7 |
–347.5 | ||
|
Other operating expenses and income |
|
|
|
|
–89.8 |
–91.0 |
–457.3 |
–335.4 | ||
|
Research and development |
–371.0 |
–348.6 |
–1,119.6 |
–1,034.6 | ||||||
|
Operating result |
|
|
|
|
333.3 |
363.5 |
693.4 |
984.4 | ||
|
Exceptional items |
|
|
|
|
–0.3 |
– |
146.6 |
–1.2 | ||
|
Earnings before interest and tax (EBIT) |
|
|
|
|
333.0 |
363.5 |
840.0 |
983.2 | ||
|
Net operating assets* |
|
|
|
|
– |
– |
17,374.0 |
18,470.5 | ||
|
Segment liabilities* |
|
|
|
|
– |
– |
–1,797.4 |
–1,898.4 | ||
|
Capital spending on property, plant and equipment |
|
|
|
85.2 |
98.3 |
251.7 |
254.2 | |||
|
Investments in intangible assets |
|
|
|
|
10.9 |
16.5 |
35.8 |
47.6 | ||
|
Depreciation and amortization |
|
|
|
|
–312.7 |
–292.9 |
–924.1 |
–740.5 | ||
|
Impairment losses |
|
|
|
|
–3.5 |
–2.4 |
–332.8 |
–36.0 | ||
|
Net cash flows from operating activities |
|
|
|
|
639.6 |
558.0 |
1,216.7 |
1,302.9 | ||
|
Net cash flows from investing activities |
|
|
|
|
–808.4 |
–4,900.5 |
–748.6 |
–3,743.4 | ||
|
Free cash flow |
|
|
|
|
481.5 |
–4,382.9 |
1,380.1 |
–3,831.7 | ||
|
Underlying free cash flow |
|
|
|
|
516.1 |
560.7 |
959.8 |
1,127.3 | ||
|
FCR in % |
|
|
|
|
20.4 |
23.0 |
12.5 |
16.7 | ||
|
ROS in % |
|
|
|
|
13.2 |
14.9 |
9.1 |
14.6 | ||